Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-07-25. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Gaddafi was later infuriated when Egypt and Syria planned the Yom Kippur War against Israel without consulting him and was angered when Egypt conceded to peace talks rather than continuing the war. Gaddafi became openly hostile to Egypt's leader, calling for Sadat's overthrow. When Sudanese President Gaafar Nimeiry took Sadat's side, Gaddafi also spoke out against him, encouraging the Sudan People's Liberation Army's attempt to overthrow Nimeiry. In 1974, Gaddafi released Abdul-Aziz Shennib, a commander under King Idris, from prison and appointed him Libyan ambassador to Jordan. Shennib had attended the Royal Military Academy Sandhurst with King Hussein of Jordan and was tasked by Gaddafi with Hussein's assassination. Shennib instead informed Hussein of the plot and defected to Jordan. Relations with Syria also soured over the events in the Lebanese Civil War. Initially, both Libya and Syria had contributed troops to the Arab League's peacekeeping force, although after the Syrian army attacked the Lebanese National Movement, Gaddafi openly accused Syrian President Hafez al-Assad of "national treason"; he was the only Arab leader to criticize Syria's actions. In late 1972 and early 1973, Libya invaded Chad to annex the uranium-rich Aouzou Strip. Intent on propagating Islam, in 1973 Gaddafi founded the Islamic Call Society, which had opened 132 centres across Africa within a decade. In 1973 he converted Gabonese President Omar Bongo, an action which he repeated three years later with Jean-Bédel Bokassa, president of the Central African Republic.
=== Charges === On January 7th, 2010, U.S. Immigration and Customs Enforcement (ICE) agents authorized by a grand jury with a search and arrest warrant entered the residence of Mahmoud Reza Banki in New York City and arrested him. He was arraigned before Judge John F. Keenan on an indictment charging him with three counts: 1. Conspiracy to violate the U.S.-imposed Iran sanctions and conspiracy to run an unlicensed money transmittal system, 2. Violation of the Iran sanctions, and 3. Running of an unlicensed money transmittal business. The indictment accused Banki of receiving $4.7 million in violation of the Iran sanctions. Prosecutors filed a superseding indictment later changing the amount to $3.4 million and adding two false statement charges to the three initial charges.
A familial form of pseudohyperkalemia, a benign condition characterised by increased serum potassium in whole blood stored at cold temperatures, also exists. This is due to increased potassium permeability in red blood cells.
=== Multinational corporations === The OECD Guidelines for Multinational Enterprises are a set of legally non-binding guidelines attached as an annexe to the OECD Declaration on International Investment and Multinational Enterprises. They are recommendations providing principles and standards for responsible business conduct for multinational corporations operating in or from countries adhering to the Declaration.
Sources: en.wikipedia.org
== Terminology == A child is referred to as the stepdaughter or stepson of their biological or adoptive parent's new spouse, and the spouse is referred to as the stepparent (father or mother) of the child. A stepparent is the spouse of someone's parent, and not their biological parent, stepfather being the male spouse and stepmother the female spouse. A step-grandparent is the step-parent of someone's parent or the parent of one's step-parent, and not someone's biological grandparent, stepgrandfather being the male one, and stepgrandmother the female one. A step-uncle is the spouse of someone's parent's sister (aunt) or brother (uncle) and is not the father of someone's cousin, except when the sibling marries another and never has children (no cousins). The sister's niece/nephew should refer to a new spouse as uncle, not step-uncle. A step-aunt is the spouse of someone's parent's brother (uncle) or sister (aunt) and is not the mother of someone's cousin, except when the sibling marries another and never had children (no cousins). The sister's niece or nephew should refer to the newest spouse as aunt, not step-aunt. Similarly, a stepsibling is the offspring of a stepparent to whom one is not biologically or adoptive related, stepbrother being the male one and stepsister the female one. A stepgrandson is the grandson of someone's spouse who one is not biologically related to. A step-granddaughter is the granddaughter of someone's spouse to whom one is not biologically or adoptive related.
=== 2010s === Stanton was elected into the Essendon leadership group for the 2010 season. Stanton amassed 477 possessions and kicked 13 goals in 20 games for an Essendon team which won seven matches and lost fifteen in a year that would see their coach, Matthew Knights, sacked one day after the conclusion of the regular season. Stanton polled six votes in the Brownlow Medal and finished fifth in the 2010 Crichton Medal with 167 votes. Stanton continued to improve during the year. Stanton led the club in kicks and handballs received and was in the top five for marks, handballs, inside-50s, rebound-50s and loose-ball gets. Into his ninth AFL season and in the Essendon leadership group, Stanton finished second in the 2011 Crichton Medal behind David Zaharakis. He played his 150th AFL game against Melbourne in Round 11. Wearing the number 5, his running and ability to accumulate possessions contributed to every victory during the 2012 season. He has now polled a career high 14 votes in the 2012 Brownlow Medal. In Round 6 of the 2012 AFL season, Stanton collected a record 193 Dream Team points in Essendon's win against the Brisbane Lions at Docklands Stadium. His statistics included: 39 disposals (from 32 kicks and 7 handballs), 17 marks and 8 tackles. As of 2015, it remains the highest Dream Team score by a midfielder. Stanton played his 200th game in Round 20, 2013 against West Coast at Etihad Stadium.
A team led by chemist Gary Rasmusson and biologist Jerry Brooks developed potential 5α-reductase inhibitors based on transition-state inhibitors, using an iterative process of molecular design, testing, and redesign. In 1992, finasteride (5 mg) was approved by the US Food and Drug Administration (FDA) for treatment of BPH, which Merck marketed under the brand name Proscar. Rasmusson and Brooks were awarded IPO's "Inventor of the Year" award in 1993 for their work on finasteride. In 1997, Merck was successful in obtaining FDA approval for a second indication of finasteride (1 mg) for treatment of male pattern hair loss, which was marketed under the brand name Propecia. It was the first 5α-reductase inhibitor to be introduced and was followed by dutasteride in 2001. The first study of finasteride in the treatment of hirsutism in women was published in 1994.
Sources: en.wikipedia.org
=== Cuticular color === Cuticular color (pigmentation of the cuticle) is a heritable component and varies from tan to black. In the mealworm beetle, evidence suggests that population level variation in cuticular color is linked to pathogen resistance in that darker individuals are more resistant to pathogens. A study found that two immune parameters related to resistance, haemocyte density and pre-immune challenge activity of phenoloxidase, were significantly higher in selection lines of black beetles compared to tan lines. Higher haemocyte density is likely indicative of a heightened immune response. There were no effects of gender on the immune traits. Cuticular color is dependent on melanin production, which requires phenoloxidase, an enzyme that is present in its inactive form inside haemocytes. This shows why darker insects have a heightened immune response and are more resistant to pathogens that invade the hemocoel via the cuticle. However, there was no significant difference in haemolymph antibacterial activity between black and tan lines, explained by how antimicrobial peptides are produced by haemocytes but are not involved in cuticular darkening. In T. molitor, the degree of cuticular melanization is a strong indicator of resistance to the entomopathogenic fungus Metarhizium anisopliae, which could be explained by the thicker and less porous cuticle displayed by darker insects compared to lighter ones.
=== DSM-5 === Anorexia nervosa is classified under the Feeding and Eating Disorders in the fifth revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). There is no specific BMI cut-off that defines low weight required for the diagnosis of anorexia nervosa. The diagnostic criteria for anorexia nervosa (all of which needing to be met for diagnosis) are:
In Rolf Singer's classification of the Agaricales mushrooms, it is also the type species of section Boletus, a grouping of about 30 related boletes united by several characteristics: a mild-tasting, white flesh that does not change colour when exposed to air; a smooth to distinctly raised, netted pattern over at least the uppermost portion of the stem; a yellow-brown or olive-brown spore print; white tubes that later become yellowish then greenish, which initially appear to be stuffed with cotton; and cystidia that are not strongly coloured. Molecular analysis published in 1997 established that the bolete mushrooms are all derived from a common ancestor, and established the Boletales as an order separate from the Agaricales. The generic name is derived from the Latin term bōlētus "mushroom", which was borrowed in turn from the Ancient Greek βωλίτης, "terrestrial fungus". Ultimately, this last word derives from bōlos/βῶλος "lump", "clod", and, metaphorically, "mushroom". The βωλίτης of Galen, like the boletus of Latin writers like Martial, Seneca and Petronius, is often identified as the much prized Amanita caesarea. The specific epithet edulis in Latin means "eatable" or "edible".
==== Carbon-nitrogen ==== Monoamine oxidase (MAO) is an extensively studied flavoenzyme due to its biological importance with the catabolism of norepinephrine, serotonin and dopamine. MAO oxidizes primary, secondary and tertiary amines, which nonenzymatically hydrolyze from the imine to aldehyde or ketone. Even though this class of enzyme has been extensively studied, its mechanism of action is still being debated. Two mechanisms have been proposed: a radical mechanism and a nucleophilic mechanism. The radical mechanism is less generally accepted because no spectral or electron paramagnetic resonance evidence exists for the presence of a radical intermediate. The nucleophilic mechanism is more favored because it is supported by site-directed mutagenesis studies which mutated two tyrosine residues that were expected to increase the nucleophilicity of the substrates.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.